There are few data on the safety of diltiazem treatment in patients with severe left ventricular dysfunction. The few data available were obtained from patients given short term intravenous diltiazem9 50 or from patients treated orally for less than 24 hours.'0 The safety of diltiazem is of more than academic interest. Adequate control of angina pectoris with nitrate preparations alone is often not possible.
Agents that block calcium entry are potentially capable of altering left ventricular function by three basic mechanisms: (a) direct peripheral arterial dilatation or left ventricular afterload reduction; (b) reflex augmentation of sympathetic nervous activity; and (c) direct myocardial inotropic depression.' 2 The first two of these effects would tend to augment performance and counterbalance the direct negative inotropic effect. The Accepted for publication 1 July 1987 agents when they are used in patients with abnormally depressed left ventricular performance.
There are few data on the safety of diltiazem treatment in patients with severe left ventricular dysfunction. The few data available were obtained from patients given short term intravenous diltiazem9 50 or from patients treated orally for less than 24 hours.'0 The safety of diltiazem is of more than academic interest. Adequate (1) normal pulmonary blood flow with greater flow to the bases than apices; (2) equal pulmonary blood flow distribution to the upper and lower lobes; (3) upper lobe blood diversion; (4) alveolar airspace oedema. The cardiothoracic ratio on each film was independently measured by each radiologist. The diameter of the heart and the maximal transverse cardiac dimension were measured to the nearest 5 mm. Others have shown that the interstudy variability of radionuclide ventriculography by this approach is independent of the day on which the study is performed."9 Differences in ejection fraction attributed to drug effect in a given patient were therefore assumed to be potentially important only if they were > 5 ejection fraction units. All patients were studied before diltiazem treatment and 17 were also studied at least 72 determine the significance of differences (mean (SD)) between two groups if the F value was significant. The proportions in two independent samples were compared by x2 analysis corrected for continuity.2' When the expected frequencies were < 5 we used Fisher's exact probability test instead.
Results
The mean and median follow up periods for the entire group of patients were 7-5 months and 6-2 months respectively (range 2 weeks to 16 months). Six patients were treated for less than two monthswith diltiazem being intentionally discontinued in five. Reasons for early discontinuation in these individuals included asymptomatic pseudo-Mobitz Type 2 second degree atrioventricular block with narrow QRS complex, intractable nausea, subsequent myocardial infarction, subsequent coronary artery vein bypass surgery, and cost containment. In an additional patient, increasing fatigue, exertional dyspnoea, and paroxysmal nocturnal dyspnoea prompted the discontinuation of diltiazem after 5 weeks' treatment.
The dose of diltiazem taken by patients (n = 16) followed for more than eight weeks (253 (59) mg/24 h) did not differ from that taken by those (n = 6) who Zema, Perlmutter, Mankes, Nikitopoulos Figure 2 shows the sequence of left ventricular ejection fraction determinations, with some patients having measurements performed off and on diltiazem on more than one occasion as mentioned above. There were significant changes in ejection fraction in five patients: in three there was an increase and in two a decrease. One of the two patients with a significant fall in ejection fraction had increasing fatigue and dyspnoea. The clinical condition of the other patient was unchanged. The cardiothoracic ratio measured by chest x ray was similar off (0 47 (0 06) and on (0 48 (0-05)) diltiazem treatment (n = 19; p = NS) (fig 3) . The cardiothoracic ratio changed by at least 0 03 in six patients-there was an increase in three and a decrease in three. Radiographic pulmonary blood flow score did not differ off (1-14 (0 6) and on (1-7 (0 9)) diltiazem (n = 19). Pulmonary blood flow score changed by at least one unit in seven patients. It increased in five and decreased in two. One patient with increasing fatigue and dyspnoea had an increase in cardiothoracic ratio and pulmonary blood flow score and a significant decrease in left ventricular ejection fraction on diltiazem treatment. 
